Have a quick look at 3 top mobile apps that can help your patients better manage a range of thyroid conditions.
Veronica Hackethal, MD
Will SGLT2 inhibitor canagliflozin prove renoprotective in T2DM patients? CANVAS study authors sought to find out.
Increased risk for CV events and severe hypoglycemia in T2D patients treated with β-blockers seems reason enough to rethink this Rx.
Click through these 5 statements about the "gliflozin" class of diabetes drugs for a test of your recall and retention.
Take our 6-question True or False spot-check quiz on ADA vaccine recommendations.
The first-to-market hybrid closed loop CGM and "smart" insulin pens are 2 of our picks for 2017’s best tech advances in diabetes management.
Is GLP-1 part of the answer to why cardiac mortality tends to be higher in diabetes patients treated with intensive glycemic control?
Five studies on the impact of diabetes drugs on CV outcomes get the editors' nod for the most promising results in 2017 diabetes research. Find out which 5!
ShugaTrak, Glucose Buddy, OnTrack -- 3 of the 5 apps we highlight that are designed to make diabetes monitoring seamless for all.
More intensive reduction of A1c, lipids, and blood pressure did, however, result in a significantly reduced rate of cerebrovascular events.